ArticleBMC cancer2025
Risk factors for cancer among patients with type 2 diabetes: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) and cancer pose significant public health challenges worldwide. This study investigated the distribution of cancer cases and associated risk factors among patients with T2DM, aiming to inform clinical practices and reduce the burden of co-morbidities.
methodsA retrospective cohort study analyzed electronic medical records of 70,073 T2DM patients admitted between 2013 and 2019. After exclusions, 3,284 individuals were included, with a median follow-up of 27 months. Associations between 38 baseline characteristics and cancer risk were first assessed using univariate Cox proportional hazards models (reported as hazard ratios [HRs] with 95% confidence intervals [CIs]). Significant predictors (p < 0.05) were further analyzed in adjusted multivariable Cox models by backward elimination (retaining 2 significant covariates).
resultsAmong the participants, 467 (14.2%) developed cancer, with digestive system cancers being the most prevalent (5.8%). The median age of participants was 58 years, with 59% being male. Risk factors for cancer among T2DM patients identified in multivariate analysis included lower serum uric acid levels (HR: 0.9970, 95% CI: 0.9942-0.9998), and higher AST/ALT ratio (HR: 1.84, 95% CI: 1.16-2.92). Specific risk factors for different types of cancer were also identified, such as lower apolipoprotein A for digestive system cancers and older age and lower serum uric acid levels for lung cancer.
conclusionsThese findings highlight the potential value of integrating cancer screening into T2DM management for high-risk patients, such as individuals with altered uric acid or liver enzyme profiles. However, the study's retrospective design and reliance on single-center data necessitate further prospective studies to validate these associations and refine biomarker-guided monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.